Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Pharma Prices Hong Kong IPO at Top of Range

publication date: Jul 7, 2014
Luye Pharma priced its Hong Kong IPO at the top end of its proposed range, placing 999.6 million shares at HK$5.92 to raise US$764 million. The shares will begin trading on Wednesday, July 9. The price reflects a price-earnings ratio of 26.6 and values Luye at $2.5 billion. Luye was listed in Singapore until 2012, when three private equity firms and the sovereign wealth fund of Singapore (plus the company’s chairman) took the company private. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital